EU Clinical Trial Information System (CTIS)

Brand Logo

Brand Logo Light

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

I searched for some studies on AstraZeneca Clinical Trials, and found these studies that may also be of interest to you.
Here is the link to my search results

Official Title

The purpose of this study is to compare Symbicort in a pressurized metered-dose inhaler (pMDI) with formoterol and placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

A comparison of Symbicort® pMDI 2 x 160/4.5 μg bid and 2 x 80/4.5 μg bid with Formoterol Turbuhaler® 2 x 4.5 μg bid and Placebo in Patients with COPD

Research Site

A 12-Month Double-blind, Double-dummy, Randomized, Parallel group, Multicenter Efficacy and Safety Study of Symbicort® pMDI 2 x 160/4.5 μg bid and 2 x 80/4.5 μg bid Compared to Formoterol Turbuhaler® 2 x 4.5 μg bid and Placebo in  Patients with COPD

A comparison of Symbicort® pMDI 2 x 160/4.5 μg bid and 2 x 80/4.5 μg bid with Formoterol Turbuhaler® 2 x 4.5 μg bid and Placebo in Patients with COPD

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=542&filename=CSR-D5899C00001.pdf

CSR-D5899C00001.pdf

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator